Soleil Research | Evidence Review
Published August 28, 2026 in The New England Journal of Medicine
Plain-Language Summary
CARDIO-TTRansform tested whether eplontersen, an antisense oligonucleotide designed to reduce transthyretin production, would improve clinical outcomes in people with transthyretin amyloid cardiomyopathy (ATTR-CM). In 1,432 adults receiving contemporary standard care, eplontersen every four weeks did not significantly reduce the prespecified composite of cardiovascular death and recurrent cardiovascular clinical events over 140 weeks compared with placebo. Serious adverse events were similar between groups.
The scientifically appropriate headline is therefore a neutral phase 3 primary result—not proof of clinical superiority. A neutral superiority result also does not prove that the two strategies are identical; the confidence interval remains compatible with a range of possible effects.
Why This Study Matters
ATTR-CM is a progressive form of cardiomyopathy caused by deposition of misfolded transthyretin in the heart. Eplontersen is an antisense oligonucleotide that reduces hepatic production of transthyretin by targeting TTR messenger RNA.
The biological rationale is compelling, but target engagement is not the same as demonstrated clinical benefit. CARDIO-TTRansform matters because it asked the more consequential question: does lowering transthyretin with eplontersen add meaningful cardiovascular benefit when patients are already receiving contemporary standard treatment?
What the Study Tested
CARDIO-TTRansform was a phase 3, international, randomized, double-blind, placebo-controlled trial. Investigators assigned patients with ATTR-CM in a 1:1 ratio to subcutaneous eplontersen 45 mg or placebo every four weeks for 140 weeks, in addition to standard treatment.
A total of 1,432 patients underwent randomization and received at least one dose: 715 in the eplontersen group and 717 in the placebo group. Mean age was 76.4 years, and 90.6% of participants were men.
The primary endpoint was a cumulative composite of cardiovascular death and recurrent cardiovascular clinical events through week 140. Because recurrent events were included, the analysis assessed the total burden of eligible events rather than only the first event experienced by each participant.
A separate baseline report from CARDIO-TTRansform showed that 57.2% of participants were receiving a transthyretin stabilizer at enrollment. This is important context: the trial evaluated the incremental effect of eplontersen in a contemporary treatment landscape rather than as an isolated stand-alone therapy.
What the Study Found
- Primary endpoint: 381 primary-endpoint events occurred in 210 patients (29.4%) assigned to eplontersen, compared with 392 events in 231 patients (32.2%) assigned to placebo. The rate ratio was 0.89 (95% CI, 0.73–1.09; P = .28).
- Cardiovascular death: 74 cardiovascular deaths occurred in the eplontersen group and 70 in the placebo group.
- Cardiovascular clinical events: 307 events occurred with eplontersen and 322 with placebo.
- All-cause death plus cardiovascular events: the rate ratio was 0.86 (95% CI, 0.71–1.04), which also did not establish a clear reduction.
- Serious adverse events: these occurred in 57.8% of patients receiving eplontersen and 59.4% receiving placebo.
The primary result did not meet the conventional threshold for statistical significance. The confidence interval crossed 1.0, so the trial did not establish superiority of eplontersen over placebo for the prespecified primary clinical outcome through 140 weeks.
Methodological Quality
Overall assessment: high-quality phase 3 randomized evidence for the primary clinical question, with a neutral superiority result that should be given greater weight than exploratory subgroup interpretations.
The trial design provides strong protection against several common sources of bias. Randomization, double blinding, placebo control, an international population, a large sample, and long follow-up make the primary comparison substantially more informative than an uncontrolled biomarker or mechanistic study.
Strengths
- Large phase 3 randomized sample of 1,432 treated participants.
- International, double-blind, placebo-controlled design.
- Long 140-week treatment and follow-up period for a progressive chronic disease.
- Clinically meaningful primary outcome incorporating cardiovascular death and recurrent cardiovascular clinical events.
- Evaluation on top of standard treatment, making the question relevant to contemporary practice.
- Prospective trial registration and prespecified primary endpoint.
- Serious adverse events were reported at similar frequencies between randomized groups.
Limitations and Cautions
- Representation: 90.6% of participants were men. A separate baseline publication reported that 88.8% of the cohort was White, limiting certainty about how precisely the findings generalize to women and more racially diverse populations.
- Composite endpoint: cardiovascular death and several types of recurrent cardiovascular clinical events were combined. Composite and recurrent-event analyses are clinically useful, but their overall estimate can obscure differences among individual components.
- Contemporary background therapy: many participants were already receiving disease-modifying transthyretin stabilizers. This improves real-world relevance but means the trial answers an incremental-efficacy question rather than whether eplontersen has biological activity in isolation.
- Evolving standard care: ATTR-CM treatment changed rapidly during the trial era, which can reduce the room for additional benefit and complicate comparisons with older studies. This is context, not a reason to discount the neutral primary result.
- Subgroup interpretation: any favorable subgroup signal should be treated as exploratory or hypothesis-generating unless supported by a prespecified, multiplicity-controlled analysis. A subgroup signal cannot override a neutral primary endpoint in the overall randomized population.
- Duration: 140 weeks is substantial, but ATTR-CM is a chronic progressive disease. Longer observation could inform durability and late outcomes, although this limitation does not change what the prespecified 140-week analysis showed.
Funding and Conflicts of Interest
The study was funded by Ionis Pharmaceuticals and AstraZeneca. Several coauthors listed in the publication were employees of one of the sponsoring companies, including authors affiliated with AstraZeneca and Ionis. The New England Journal of Medicine provides individual author disclosure forms with the article.
The publication also acknowledges editorial assistance from Rose Follis, Ph.D., and Ryan Riley, Ph.D., of Ashfield MedComms, an Inizio company. These relationships are important to disclose because the sponsors have a direct commercial interest in eplontersen. They do not, by themselves, invalidate a randomized result. They do reinforce the importance of prioritizing prespecified outcomes, transparent reporting, independent scrutiny, and later replication or regulatory review when interpreting secondary and subgroup findings.
Soleil Insight
Mechanistic plausibility does not substitute for incremental clinical benefit.
Eplontersen targets a biologically compelling pathway, but CARDIO-TTRansform did not demonstrate superiority on its prespecified primary clinical endpoint in the overall population through 140 weeks. In a rapidly evolving ATTR-CM treatment landscape, a new therapy must show that its biological effect adds meaningful benefit beyond what patients already receive.
The disciplined interpretation is therefore neither that transthyretin lowering is biologically irrelevant nor that eplontersen has been proven clinically beneficial for ATTR-CM. The neutral primary result deserves more evidentiary weight than any nominally favorable secondary or subgroup signal.
Original Publication
Fontana M, Masri A, Solomon SD, et al. Eplontersen for Transthyretin Amyloid Cardiomyopathy. N Engl J Med. Published online August 28, 2026. DOI: 10.1056/NEJMoa2608510.
ClinicalTrials.gov: NCT04136171.
Featured Image Attribution
Featured image: Nephron / Wikimedia Commons, licensed under CC BY-SA 3.0. The image is a high-magnification H&E micrograph illustrating cardiac amyloidosis and does not depict a CARDIO-TTRansform participant or study specimen. Image source.
Advancing Science. Empowering Humanity.
Soleil Research™ provides evidence-focused scientific education and does not replace clinical judgment, institutional policy, or individualized medical care.